OIM
ADAP

Oracle Investment Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Oracle Investment Management’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-52,921
Closed -$304K – 19
2018
Q4 		$304K Sell
52,921
-844,573
-94% -$6.23M 0.09% 16
2018
Q3 		$12.2M Sell
897,494
-496,249
-36% -$5.2M 2.66% 8
2018
Q2 		$16.5M Buy
1,393,743
+63,673
+5% +$794K 4% 6
2018
Q1 		$14.9M Buy
1,330,070
+297,349
+29% +$2.6M 3.62% 7
2017
Q4 		$6.9M Buy
1,032,721
+330,860
+47% +$2.56M 1.37% 10
2017
Q3 		$5.75M Buy
+701,861
New +$4.38M 0.94% 12

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Oracle Investment Management's ADAP Position: Q1 2019 in Review

Oracle Investment Management sold out of Adaptimmune Therapeutics (ADAP) in Q1 2019, closing a stake of 52,921 shares — an estimated $304K sold.

Oracle Investment Management first reported a position in ADAP in Q3 2017 and held it in 6 quarters. The position peaked at $16.5M in Q2 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q1 2019.

  • Oracle Investment Management reported no remaining Adaptimmune Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Oracle Investment Management sold 52,921 Adaptimmune Therapeutics shares in Q1 2019, an estimated $304K.
  • Oracle Investment Management first reported a position in Adaptimmune Therapeutics in Q3 2017 and held it in 6 quarters.
  • Oracle Investment Management's Adaptimmune Therapeutics position peaked at $16.5M in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q1 2019.

Based on Oracle Investment Management's 13F filing for Q1 2019, filed 15 May 2019.